High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: anin vivostudy using magnetic resonance imaging
- 20 August 2007
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 68 (3) , 361-368
Abstract
Summary: Objective Left ventricular (LV) hypertrophy and myocardial fibrosis are considered the main pathological features of acromegalic cardiomyopathy. The aim of the study was to evaluate the proportion of LV hypertrophy and the presence of fibrosis in acromegalic cardiomyopathyin vivousing cardiac magnetic resonance (CMR).Design and patients Fourteen consecutive patients (eight women, mean age 46 ± 10 years) with untreated active acromegaly were submitted to two‐dimensional (2D) colour Doppler and integrated backscatter (IBS) echocardiography and CMR.Measurements LV volume, mass and wall thickness and myocardial tissue characterization (IBS and CMR).Results On echocardiography: mean LV mass (LVM) and LVM index (LVMi) were 209 ± 48 g and 110 ± 24 g/m2, respectively; hypertrophy was revealed in five patients (36%); abnormal diastolic function [evaluated by isovolumic relaxation time (IVRT) or early (E) to late or atrial (A) peak velocities (E/A ratio)] was found in four patients (29%). Systolic function evaluated by measuring LV ejection fraction (LVEF) was normal (mean 72 ± 12%) in all patients. Six patients (43%) had increased IBS (mean 57·4 ± 6·2%). On CMR: mean LVM and LVMi were 151 ± 17 g and 76 ± 9 g/m2, respectively; 10 patients (72%) had LV hypertrophy. Contrastographic delayed hyperenhancement was absent in all patients; on the contrary, mild enhancement was revealed in one patient. Systolic function was normal in all patients (LVEF 67 ± 11%). LVMi was not related to serum IGF‐1 concentrations or the estimated duration of disease.Conclusions CMR is considered to be the gold standard for evaluating cardiac hypertrophy, fibrosis and systolic function. Using CMR, 72% patients with untreated active acromegaly had LV hypertrophy, which was only detected in 36% patients by echocardiography. However, cardiac fibrosis was absent in all patients irrespective of the estimated duration of disease. Although a very small increase in collagen content (as suggested by increased cardiac reflectivity at IBS), not detectable by CMR, could not be ruled out, it is unlikely that it would significantly affect cardiac function.Keywords
This publication has 44 references indexed in Scilit:
- Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and ManagementEndocrine Reviews, 2004
- Cardiovascular Function in AcromegalyEndocrine Reviews, 2003
- Reversal of acromegalic cardiomyopathy in young but not in middle‐aged patients after 12 months of treatment with the depot long‐acting somatostatin analogue octreotideClinical Endocrinology, 2003
- Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegalyEuropean Journal of Endocrinology, 2002
- Growth hormone and the heartClinical Endocrinology, 2001
- Blood pressure-independent cardiac hypertrophy in acromegalic patientsJournal Of Hypertension, 1999
- Echocardiographic evidence for a direct effect of GH/IGF‐I hypersecretion on cardiac mass and function in young acromegalicsClinical Endocrinology, 1998
- Cardiovascular aspects in acromegaly: Effects of treatmentMetabolism, 1996
- Growth Hormone and the HeartEndocrine Reviews, 1994
- Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegalyThe Journal of Clinical Endocrinology & Metabolism, 1993